Innovative therapies under clinical development for ALS treatment. Part 2: biologics and natural products.

Huang CS, Sanchez-Santos C, Martinez-Gonzalez L, Gil C, Martinez A

Open source

DOI
10.1080/13543784.2026.2729512
Published
2026 Sep 12
Container
Expert opinion on investigational drugs
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/13543784.2026.2729512,
  title = {Innovative therapies under clinical development for ALS treatment. Part 2: biologics and natural products.},
  author = {Huang CS and Sanchez-Santos C and Martinez-Gonzalez L and Gil C and Martinez A},
  year = {2026},
  journal = {Expert opinion on investigational drugs},
  doi = {10.1080/13543784.2026.2729512},
  url = {https://doi.org/10.1080/13543784.2026.2729512}
}

RIS

TY  - JOUR
TI  - Innovative therapies under clinical development for ALS treatment. Part 2: biologics and natural products.
AU  - Huang CS
AU  - Sanchez-Santos C
AU  - Martinez-Gonzalez L
AU  - Gil C
AU  - Martinez A
PY  - 2026
JO  - Expert opinion on investigational drugs
DO  - 10.1080/13543784.2026.2729512
UR  - https://doi.org/10.1080/13543784.2026.2729512
ER  - 

APA

CS, H., C, S., L, M., C, G., & A, M. (2026). Innovative therapies under clinical development for ALS treatment. Part 2: biologics and natural products.. Expert opinion on investigational drugs. https://doi.org/10.1080/13543784.2026.2729512

Source records